Lilly Sees More Dealmaking as GLP-1 Wins Expand Market
Eli Lilly’s GLP-1 drugs have changed the game in obesity and diabetes. This article explains why Lilly Sees More Deal...
Real-world success stories illustrate how households adapt Zero Based Budgeting to save more and reduce waste.
17,559 articlesEli Lilly’s GLP-1 drugs have changed the game in obesity and diabetes. This article explains why Lilly Sees More Deal...
Two biotech contenders, Recursion Pharmaceuticals and Summit Therapeutics, face off in a year of uncertainty and oppo...
When a legend steps into the Hall of Fame, the moment isn’t just about applause. It’s a reminder that big recognition...
A Tony moment becomes a teachable moment for money and planning. This feature breaks down how Broadway earnings work,...
As self-driving tech moves from labs to city streets, control of the platform becomes the real battleground. This art...
A bipartisan bill would establish a Federal Cryptocurrency Theft Task Force within the DOJ, aiming to coordinate pros...
Cardano faces a pivotal test as founder Charles Hoskinson lays out a four-layer rescue plan blending governance refor...
From repeated loan denials to a growing 10+ unit multifamily portfolio, this deal diary-style story reveals the strat...
A thoughtful look at Xeris Biopharma's Q4 2025 earnings, the company’s pipeline milestones, and what xeris biopharma ...
DocuSign's 2026 earnings narrative centers on ARR expansion, margin discipline, and stronger cash flow in a competiti...
Oklo stock climbing higher this week is driven by regulatory progress on its Aurora reactor and broader interest in a...
A biotech stock has surged 355%, catching the eye of every investor from day traders to pension funds. A prominent he...